Biomea Fusion (BMEA) to Release Quarterly Earnings on Thursday

Biomea Fusion (NASDAQ:BMEA - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect Biomea Fusion to post earnings of ($0.90) per share for the quarter.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.19. On average, analysts expect Biomea Fusion to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Biomea Fusion Trading Down 4.8 %

BMEA stock traded down $0.11 during trading on Friday, reaching $2.19. 745,392 shares of the stock were exchanged, compared to its average volume of 910,038. The firm has a market capitalization of $82.28 million, a price-to-earnings ratio of -0.55 and a beta of -0.07. The business has a 50 day moving average price of $2.39 and a 200-day moving average price of $4.91. Biomea Fusion has a 1 year low of $1.53 and a 1 year high of $13.43.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BMEA shares. D. Boral Capital reissued a "buy" rating and set a $16.00 target price on shares of Biomea Fusion in a research note on Wednesday, March 19th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Biomea Fusion in a report on Monday, March 31st. Barclays decreased their price target on Biomea Fusion from $11.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 2nd. Finally, Oppenheimer set a $10.00 price objective on Biomea Fusion in a research note on Monday, March 24th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Biomea Fusion presently has an average rating of "Buy" and a consensus price target of $23.91.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.